CN1679684A - Rubber plaster for treating insufficient cold type chronic gstroentertis and rheumatic arthritis and preparation thereof - Google Patents
Rubber plaster for treating insufficient cold type chronic gstroentertis and rheumatic arthritis and preparation thereof Download PDFInfo
- Publication number
- CN1679684A CN1679684A CN 200510004819 CN200510004819A CN1679684A CN 1679684 A CN1679684 A CN 1679684A CN 200510004819 CN200510004819 CN 200510004819 CN 200510004819 A CN200510004819 A CN 200510004819A CN 1679684 A CN1679684 A CN 1679684A
- Authority
- CN
- China
- Prior art keywords
- rubber
- treatment
- emplastrum
- rheumatic arthritis
- chronic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000003068 rheumatic fever Diseases 0.000 title claims abstract description 43
- 230000001684 chronic effect Effects 0.000 title claims description 38
- 238000002360 preparation method Methods 0.000 title claims description 18
- 239000011505 plaster Substances 0.000 title abstract description 30
- 208000005577 Gastroenteritis Diseases 0.000 claims abstract description 26
- 239000011159 matrix material Substances 0.000 claims abstract description 8
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 239000000843 powder Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 claims description 15
- 239000011787 zinc oxide Substances 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 13
- 239000006071 cream Substances 0.000 claims description 10
- 238000007598 dipping method Methods 0.000 claims description 9
- 239000002674 ointment Substances 0.000 claims description 9
- 239000000758 substrate Substances 0.000 claims description 9
- 239000011248 coating agent Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- 238000005520 cutting process Methods 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000005470 impregnation Methods 0.000 claims description 6
- 235000002566 Capsicum Nutrition 0.000 claims description 5
- 239000006002 Pepper Substances 0.000 claims description 5
- 235000016761 Piper aduncum Nutrition 0.000 claims description 5
- 235000017804 Piper guineense Nutrition 0.000 claims description 5
- 235000008184 Piper nigrum Nutrition 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 3
- 244000203593 Piper nigrum Species 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 43
- 244000080208 Canella winterana Species 0.000 abstract 2
- 235000008499 Canella winterana Nutrition 0.000 abstract 2
- 229940017545 cinnamon bark Drugs 0.000 abstract 2
- 235000002568 Capsicum frutescens Nutrition 0.000 abstract 1
- 240000008574 Capsicum frutescens Species 0.000 abstract 1
- 244000273928 Zingiber officinale Species 0.000 abstract 1
- 235000006886 Zingiber officinale Nutrition 0.000 abstract 1
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 235000008397 ginger Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 49
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 32
- 208000002193 Pain Diseases 0.000 description 31
- 230000036407 pain Effects 0.000 description 31
- 208000011580 syndromic disease Diseases 0.000 description 29
- 208000024891 symptom Diseases 0.000 description 28
- 201000010099 disease Diseases 0.000 description 27
- 238000012360 testing method Methods 0.000 description 27
- 229940079593 drug Drugs 0.000 description 18
- 230000010354 integration Effects 0.000 description 17
- 206010012735 Diarrhoea Diseases 0.000 description 16
- 208000007882 Gastritis Diseases 0.000 description 14
- 208000023652 chronic gastritis Diseases 0.000 description 14
- 206010016326 Feeling cold Diseases 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 11
- 239000008280 blood Substances 0.000 description 10
- 206010063659 Aversion Diseases 0.000 description 9
- 206010009900 Colitis ulcerative Diseases 0.000 description 9
- 201000006704 Ulcerative Colitis Diseases 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 238000010792 warming Methods 0.000 description 9
- 208000019790 abdominal distention Diseases 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000036528 appetite Effects 0.000 description 7
- 235000019789 appetite Nutrition 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 230000004596 appetite loss Effects 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 229960004756 ethanol Drugs 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 208000019017 loss of appetite Diseases 0.000 description 6
- 235000021266 loss of appetite Nutrition 0.000 description 6
- 229940074869 marquis Drugs 0.000 description 6
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 201000006549 dyspepsia Diseases 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 238000013139 quantization Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 241000721047 Danaus plexippus Species 0.000 description 4
- 244000153234 Hibiscus abelmoschus Species 0.000 description 4
- 241000722363 Piper Species 0.000 description 4
- 238000001467 acupuncture Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000004062 sedimentation Methods 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- 206010058314 Dysplasia Diseases 0.000 description 3
- 208000004044 Hypesthesia Diseases 0.000 description 3
- 206010054949 Metaplasia Diseases 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 208000021735 chronic enteritis Diseases 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 206010009887 colitis Diseases 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 230000003118 histopathologic effect Effects 0.000 description 3
- 208000034783 hypoesthesia Diseases 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000002175 menstrual effect Effects 0.000 description 3
- 230000015689 metaplastic ossification Effects 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 208000019914 Mental Fatigue Diseases 0.000 description 2
- 206010034568 Peripheral coldness Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 229940025250 camphora Drugs 0.000 description 2
- 239000010238 camphora Substances 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000036548 skin texture Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000031636 Body Temperature Changes Diseases 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- 235000015655 Crocus sativus Nutrition 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000019637 Infantile Diarrhea Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- WVVOBOZHTQJXPB-UHFFFAOYSA-N N-anilino-N-nitronitramide Chemical compound [N+](=O)([O-])N(NC1=CC=CC=C1)[N+](=O)[O-] WVVOBOZHTQJXPB-UHFFFAOYSA-N 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010056626 Pseudopolyp Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003500 flue dust Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine in the form of adhesive plaster for treating chronic gastroenteritis and rheumatic arthritis is prepared proportionaly from hot pepper, fresh (or dried) ginger, cinnamon bark oil, cinnamon bark oil and matrix of plaster.
Description
Technical field
The present invention relates to a kind of treatment asthenic cold type chronic gastroenteritis, rheumatic arthritis rubber-emplastrum and preparation method thereof.
Background technology
Ancients' cloud " all medicines less than, pin too late, must first moxibustion it " the characteristic curative effect of moxibustion therapy, traditional moxibustion therapy, how based on the burning Folium Artemisiae Argyi, or be Ai Zhuan or for moxa roll, body surface is produced warm stimulation through the cave, make heating power penetrate skin, and conducted by meridians that globality is cured the disease and health-care effect.Although moxibustion therapy has the merit of " warm promoting blood circulation; QI and blood regulating; by cold tonify deficiency; strengthening vital QI to eliminate pathogenic factors ", to a little less than the deficiency of YANG QI, deficiency and coldness diseases such as disease, prolonged illness asthenia are taken off in cold coagulation stasis, the accurate flaccidity syndrome and arthralgia syndrome of fainting, phlegm retention, chronic diarrhea, apoplexy that tall and erect the effect arranged, to increase body constitution, body-building is prolonged life that good effectiveness is also arranged, but it also has weak point: 1, complex operation is time-consuming; 2, can cause part patient skin causalgia or burn, foaming, suppuration; 3, the Indoor Combustion Folium Artemisiae Argyi produces bigger smog and the more flue dust of burning back generation; 4, during careless manipulation, the anxiety of the clothing of burning out is arranged.
Therefore the inventor develops a kind of existing moxibustion effect, and the method that can overcome the above-mentioned drawback of moxibustion again is to substitute moxibustion, and not only determined curative effect has wide clinical prospect, produces bigger social benefit, for the patient brings glad tidings.
Summary of the invention
The purpose of this invention is to provide a kind of treatment asthenic cold type chronic gastroenteritis, rheumatic arthritis rubber-emplastrum and preparation method thereof, overcome the shortcoming of said medicine, have advantage easy to use, evident in efficacy, that have no side effect.
The objective of the invention is to be achieved through the following technical solutions:
A kind of treatment asthenic cold type chronic gastroenteritis, rheumatic arthritis rubber-emplastrum are by the unguentum that comprises that following weight portion raw material is made: Fructus Capsici 3.8-5.4, Rhizoma Zingiberis Recens or Rhizoma Zingiberis 2-5, Oleum Cinnamomi 0.1-0.3; And rubber-emplastrum substrate pharmaceutically commonly used.
Described raw material is following weight portion raw material: Fructus Capsici 4.6, Rhizoma Zingiberis Recens or Rhizoma Zingiberis 3.5, Oleum Cinnamomi 0.2.
Rubber-emplastrum matrix optimization of the present invention is rubber, zinc oxide, Colophonium, a lanoline ratio matrix prepared routinely.
The proportioning ratio of described matrix components rubber, zinc oxide, Colophonium, lanoline is preferably (0.5-2.5): (0.5-2.5): (0.4 :-2.5): (0.1-0.55).The proportioning ratio of described matrix components rubber, zinc oxide, Colophonium, lanoline is well 0.5: 0.5: 0.4: 0.1,1: 1: 1: 0.22 or 1.5: 1.5: 1.5: 0.33.
Described treatment asthenic cold type chronic gastroenteritis, rheumatic arthritis rubber-emplastrum also comprise following weight portion raw material: Cortex Cinnamomi 0.75-1.35 is preferably following weight portion: Cortex Cinnamomi 1.05.
The present invention also provides above-mentioned a kind of preparation method for the treatment of asthenic cold type chronic gastroenteritis, rheumatic arthritis rubber-emplastrum, may further comprise the steps: Rhizoma Zingiberis is broken into coarse powder or Rhizoma Zingiberis Recens drying, is broken into coarse powder; Pepper drying is broken into coarse powder; Mix, the mixture alcohol dipping, impregnation liquid filters, and filtrate recycling ethanol is condensed into clear paste, adds rubber-emplastrum substrate pharmaceutically commonly used, adds the Oleum Cinnamomi mixing again, makes coating, is coated with cream, cutting, the lid lining is cut into pieces, promptly.
In the preparation method of the present invention, preferred mixture alcohol dipping three times, 24 hours for the first time, 72 hours for the second time, 48 hours for the third time, impregnation liquid filtered, merging filtrate reclaims ethanol, and being condensed into relative density is the clear paste of 1.3-1.35 (70 ℃), the substrate that adding is made by rubber, zinc oxide, Colophonium, lanoline, add the Oleum Cinnamomi mixing again, make coating, be coated with cream, cutting, the lid lining.
Above-mentioned preparation method also comprises: the Cortex Cinnamomi drying is broken into coarse powder, adds said mixture, use alcohol dipping.
Function of the present invention cures mainly: promoting the flow of QI-blood by warming the meridian, jiao dispelling cold and analgesia.Be used for back due to the wind-cold channel blocking network, extremities joint cold type of pain; And the coldness and pain in the epigastrium that stops causing in the wind and cold, deficiency and coldness is had loose bowels; Chronic asthenic cold type gastroenteritis, chronic rheumatic arthritis are seen above-mentioned patient.
Using method: external, according to disease, paste one by the acupuncture point.
Medicine of the present invention is based on following mechanism: we be " this thing difficulty is known ", " Li Yue Pianwen, Rhymed Discourse for Topical Remedies " for moxibustion on the basis of proved recipe, verify repeatedly, study and form through clinical.The side is monarch with the Fructus Capsici, and this thing Da Xin, big heat have temperature by cold-evil, the merit that restores menstrual flow and invigorates blood circulation, " property of medicine is examined " calls it " warming spleen and stomach for dispelling cold removes the wind diaphoresis, goes cold addiction ", " food compatibility and incompatibility of drugs " speech " warming the middle warmer and descending qi; dispelling cold and removing dampness ", and " medicine inspection " then claims its " promoting the circulation of blood of dispeling the wind, cold expelling resolving depression ".Right this product external studies show that it can make local skin vasoreflex expansion, promotes the vigorous of local blood circulation, and the intense stimulus sensory nerve ending, causes warming sense.This shows, execute this product in body surface on the cave, the not only desirable warming sense that it causes and for moxibustion, and its hot property go into the cave follow through and cold expelling, can unobstructed QI and blood and pain relieving, so with thinking monarch.The Cortex Cinnamomi that Fang Yixin is sweet, hot is a minister, and both principal drug assistance stimulated the menstrual flow by cold, and himself is complement sun, warming the spleen and stomach, removing accumulated cold again, and promoting blood circulation is longer than and is exempted from the numbness pain relieving, " property of medicine class is bright " cloud: " yang-energy can be guided in osmanthus, and a surname's promoting blood circulation makes the QI and blood colleague.So ", Fructus Capsici and Cortex Cinnamomi match, and by the merit multiplication of cold inducing menstruation to relieve menalgia, the merit that hot a surname that looses leads is more violent.Be assistant again with the Rhizoma Zingiberis Recens, strengthen on the one hand the dispel effect of cold expelling heresy of monarch, ministerial drug, strengthen monarch, ministerial drug on the other hand, make QI of channels and collaterals speed logical hot stimulation through the cave.All medicines are harmonious, make the rubber plaster, effect is collaborative, and hot to restore menstrual flow and invigorate blood circulation, heat is with dispersing cold for relieving pain, so cold-evil visitor is cut down card due to the body, subsides in through the cave, make the property of medicine penetrate the acupuncture point, follow through and cloth reach the whole body, thereby reach the cold-evil loose, through ruton, QI and blood and, the pain purpose of ending, play the good result that substitutes moxibustion.
The rubber-emplastrum of treatment chronic asthenic cold type gastroenteritis of the present invention, chronic rheumatic arthritis has the following advantages: rubber-emplastrum of the present invention is a kind of plaster preparation that replaces warm moxibustion therapy, be that one of Chinese medicine compound preparation improves greatly, filled up the blank of moxibustion therapy.The medical material that will have unique curative effect, compatibility in proportion makes that plaster is easy to use, steady quality, determined curative effect.
The present invention treats the advantage of the rubber-emplastrum of chronic asthenic cold type gastroenteritis, chronic rheumatic arthritis for proof, carried out following examples 1 rubber-emplastrum (to call in the following text: clinical trial Dai wen moxibustion plaster) and pharmacological testing:
1. test method
Adopt random packet, the positive drug parallel control, double blinding is observed, the multi-center clinical trial design
1.1 experimenter source and sample content
The experimenter derives from the outpatient service or the inpatient of each clinic test center.With reference to the regulation of " medicine registration management way " (try) the relevant relevant sample content of III clinical trial phase, intend including in observation and meet the scheme case and be no less than 400 examples.Treatment is organized in 300 examples, cold dampness accumulation pattern rheumatic arthritis (chronic phase) 120 examples, asthenic cold type chronic gastritis, each 90 example of asthenic cold type chronic nonspecific colitis: in matched group 100 examples, cold-damp resistance network rheumatic arthritis (chronic phase) 40 examples, asthenic cold type chronic gastritis, each 30 example of asthenic cold type chronic nonspecific colitis.Group comes off the case number average must not be above 20%.
1.2 group technology and blind method are implemented
Adopt statistical software establishment random coded table (blind table) and medicine coding schedule.The test drug peace is required unitizing according to blind method, number according to the medicine coding schedule then.In the process of the test, researcher is included serial number in according to case, takes the medicine in the corresponding numbering packing.All clinical trial finishes, and data management work is finished, open-blind after the data interlock.
2. curative effect observation: disease is levied the scalar quantization table
2.1 syndrome of cold-dampness blocking collaterals and rheumatic arthritis (chronic phase):
(1) related symptoms and sign: arthralgia, arthroncus, articular pain, the joint joint stuffiness, the joint is done cold, aversion to wind and cold, limbs are heavy, and the tongue pulse condition changes.The tongue pulse condition is put down in writing strictly according to the facts.Disease is levied grade scale and is seen " syndrome of cold-dampness blocking collaterals and rheumatic arthritis (chronic phase) disease is levied the scalar quantization table ", arthralgia wherein, arthroncus, articular pain, the joint joint stuffiness, the cold primary symptom that is is made in the joint, light, in, weigh three grades and remember 2,4,6 fens respectively; Aversion to wind and cold, limbs are heavy to be time disease, light, in, weigh three grades and remember 1,2,3 fen respectively.
(2) physico-chemical examination: anti-" O ", erythrocyte sedimentation rate, c reactive protein.
Syndrome of cold-dampness blocking collaterals and rheumatic arthritis (chronic phase) disease is levied the scalar quantization table
| Gently | In | Heavy | |
| Arthralgia | Pain is light, still can stand, or only send out when fatigue or Changes in weather. | Pain is heavier, and work and rest are affected | Pain is serious, is difficult to stand, and has a strong impact on work and rest |
| Articular pain | Light tenderness, the patient claims to have pain | The moderate tenderness still can be stood | The severe tenderness, pain can not be touched. |
| The joint joint stuffiness | Joint motion is slightly limited, and range of motion reduces＜1/3 | Joint motion is obviously limited, and range of motion reduces 〉=1/3 | Joint motion is seriously limited, and range of activity reduces 〉=2/3 |
| Arthroncus | Slight swollen, skin texture shoals, and the bone sign is still obvious | Swelling is more obvious, and skin texture disappears substantially, and the bone sign is not obvious | Swelling is serious, and skin is tight, the bone marks obliterated |
| The joint is done cold | Joint aversion to wind and cold only, that touches is not cool | The joint aversion to wind and cold, the cold of touching, happiness temperature | The joint aversion to wind and cold is obvious, and that touches is cold, the Chang Jiayi protection |
| Aversion to wind and cold | Idol has | Often have, but need not add clothing | Continue to exist, need add clothing |
| Limbs are heavy | It is heavy to feel slightly | Limbs are heavy, movable feel effort | Heavy difficult act the during limbs are heavy |
2.2 deficiency-cold syndrome and chronic gastritis, chronic non-specific ulcerative colitis:
(1) related symptoms and sign: mainly observe coldness and pain in the epigastrium, loose stool and diarrhea or rare half congealed, indigestion and loss of appetite lack of appetite, coldness of the body with chills, spiritlessness and weakness, abdominal distention after meal, the tongue pulse condition changes.The tongue pulse condition is put down in writing strictly according to the facts.Disease is levied grade scale and is seen " deficiency-cold syndrome and chronic gastritis, chronic non-specific ulcerative colitis disease are levied the scalar quantization table ", coldness and pain in the epigastrium wherein, loose stool or have loose bowels, indigestion and loss of appetite lack of appetite is a primary symptom, light, in, weigh three grades and remember 2,4,6 fens respectively; Coldness of the body with chills, spiritlessness and weakness, abdominal distention after meal are time disease, light, in, weigh three grades and remember 1,2,3 fen respectively
Asthenic cold type chronic gastritis, chronic non-specific ulcerative colitis disease are levied the scalar quantization table
| Gently | In | Heavy | |
| Coldness and pain in the epigastrium | Slightly, dull pain, accidental | Dull pain or distending pain, outbreak every day for several times | Severe pain or angor, outbreak repeatedly |
| Loose stool and diarrhea | Be less than every day 3 times | Every day 3-6 time | Every day is more than 7 times |
| Loose stool | It is shapeless to defecate | Every day 2-3 time, the loose stool | Every day is more than 4 times, and is just rare half congealed |
| Indigestion and loss of appetite lack of appetite | Loss of appetite, appetite subtracts slightly | Inappetence, appetite reduces | Anorexia all day, appetite obviously reduces |
| Coldness of the body with chills | Body temperature Chang Buneng reaches normal level, no matter winter summer-heat hands and feet coolness. | Regular be afraid of cold or winter brothers ice-coldly owe warm, need put on more clothes more | Conscious being afraid of cold worn clothes obviously many than ordinary person |
| Spiritlessness and weakness | Lassitude is felt asthenia slightly, can adhere to light physical labor | Spirit is tired, drowsy, and asthenia is supported daily routines more reluctantly | Spirit is extremely tired, and myasthenia of limbs can not be adhered to daily routines, |
| Abdominal distention after meal | Feel abdominal distention after the food slightly | Abdominal distention after meal is heavier, continues more than 2 hours | The food back is abdominal distention obviously, continues more than 4 hours |
(2) physico-chemical examination: 1. chronic gastritis: fibergastroscopy and gastric mucosa histology biopsy; 2. chronic nonspecific ulcer colonitis: fibercolonscopy and enteroscopy and intestinal mucosa histology biopsy, stool routine examination inspection.
3. Therapeutic Method
3.1 test drug
(1) is subjected to reagent: Dai wen moxibustion plaster
(2) contrast medicine: 1. cold dampness accumulation pattern rheumatic arthritis (chronic phase): Moschus Analgesic Unguentum, promulgated by the ministries or commissions of the Central Government 8 208 pages are recorded.Prescription is made up of Semen daturae fluid extract, Radix Illicii Lanceolati, Fructus Capsici, Moschus, Radix Aconiti, methyl salicylate, Camphora.The function cold expelling is invigorated blood circulation, analgesia.Be used for rheumatic arthralgia, articular sprain is produced authentication code: the accurate word Z43020486 of traditional Chinese medicines by Hengyang Sanitary Material Factory, Hunan Prov..2. asthenic cold type chronic gastritis, chronic non-specific ulcerative colitis: SHUFU TIEGAO, promulgated by the ministries or commissions of the Central Government 14 177 pages are recorded, and prescription is made up of Mentholum, Rhizoma Zingiberis Recens cream, Camphora cream.The function warming spleen and stomach for dispelling cold, promoting the circulation of QI to relieve pain.Be used for gastric abscess, abdominal pain and distension is felt sick, vomiting, inappetence, borborygmus diarrhea, infantile diarrhea.Produce authentication code: the accurate word Z37021126 of traditional Chinese medicines by Jinan Sanitary Materials Factory.
The contrast medicine is selected foundation: Dai wen moxibustion plaster is an external rubber paste formulation, requires should adopt same drug form in principle from comparability, and blind method is observed has feasibility.By retrieval, do not find the lamellar rubber paste formulation identical with the Dai wen moxibustion plaster main disease to be treated.Select the contrast medicine so divide sick the kind.Last art Moschus Analgesic Unguentum, SHUFU TIEGAO are with consistent for warm moxa-preparation type, and function is basic identical.Cold dampness accumulation pattern chronic rheumatic arthritis, asthenic cold type chronic gastroenteritis that the main syndrome of two medicines divides other and Dai wen moxibustion plaster to be cured mainly are approximate.And be the national standard medicine, therefore be chosen as the contrast medicine.
3.2 usage and dosage:
(1) treatment group: use Dai wen moxibustion plaster.External, according to disease, except that affected part (Ashi point), and by specification selects the cave, pastes one in each cave, exchanges cards containing all personal details and become sworn brothers 1 time in 24 hours.
(2) matched group: cold dampness accumulation pattern rheumatic arthritis (chronic phase) patient uses Moschus Analgesic Unguentum; Asthenic cold type chronic gastritis, chronic nonspecific ulcer colonitis patient use SHUFU TIEGAO.External, according to disease, except that affected part (Ashi point), and by specification selects the cave, pastes one at each acupuncture point, exchanges cards containing all personal details and become sworn brothers 1 time in 24 hours.
3.3 journey:
Test group, matched group were 1 course of treatment with 45 days all.
3.4 and medication
In the clinical observation process, tried case all must not take or adopt with the observed disease of this clinical trial serve as adapt to disease in, western drug or other treatment method.
4. curative effect judging standard
With reference to " the clinical research guideline of new Chinese medicine treatment numbness disease .-curative effect determinate standard ", " the clinical research guideline-curative effect of disease criterion of new Chinese medicine treatment rheumatoid arthritis; therapeutic effect of syndrome criterion ", " the clinical research guideline curative effect of disease criterion of new Chinese medicine treatment epigastric fullness; therapeutic effect of syndrome criterion; cardinal symptom curative effect determinate standard ", " the clinical research guideline-comprehensive therapeutic effect criterion of new Chinese medicine treatment chronic non-specific ulcerative colitis; therapeutic effect of syndrome criterion; cardinal symptom curative effect determinate standard " is worked out.
4.1 syndrome of cold-dampness blocking collaterals and deficiency-cold syndrome therapeutic effect of syndrome criterion:
Subtracting the branch rate by treatment back syndrome integration judges.
Integration subtracts branch rate=[integration before (integration before the treatment-treatment back integration)/treatment] * 100%.
(1) clinical recovery: the syndrome integration subtracts branch rate 〉=95%.
(2) produce effects: the syndrome integration subtracts branch rate 〉=70%.
(3) effective: the syndrome integration subtracts branch rate 〉=30%.
(4) invalid: the syndrome integration subtracts branch rate＜30%.
4.2 the efficacy assessment standard of cardinal symptom or sign:
(1) clinic control: after finishing the course of treatment, Sx disappears.
(2) produce effects: after finishing the course of treatment, the symptom and sign classification reduces 2 grades.
(3) effective: after finishing the course of treatment, the symptom and sign classification reduces 1 grade.
(4) invalid: as not reach the following standard of effectively stating.
4.3 disease comprehensive therapeutic effect criterion:
(1) rheumatic arthritis (chronic phase) comprehensive therapeutic effect criterion:
1. clinic control: symptom, sign all disappear, and integration reduces 〉=95%, and it is normal that the function of joint activity recovers, and main doctor trained in Western medicine physico-chemical examination index is normal.
2. produce effects: cardinal symptom, sign are obviously improved, and integration reduces 〉=75%, and function of joint is recovered substantially, can participate in operate as normal and work, and main doctor trained in Western medicine physico-chemical examination index is obviously improved or near normal.
3. effective: cardinal symptom, body prove to show and improve that integration reduces 〉=35%, and function of joint is recovered substantially or had clear improvement, and live to have can not take care of oneself to transfer to can take care of oneself, or the work ability to work of mistake cloud are recovered to some extent.Main doctor trained in Western medicine physico-chemical examination index makes moderate progress.
4. invalid: as not reach above-mentioned effective standard.
(2) chronic gastritis comprehensive therapeutic effect criterion:
1. clinic control: symptom, sign all disappear, and integration reduces 〉=95%.Gastroscope check mucosa chronic inflammatory disease is clearly better and reaches slightly, and histopathologic examination's body of gland atrophy, intestinal epithelial metaplasia and dysplasia recover normal or disappear.
2. produce effects: cardinal symptom, sign are obviously improved, and integration reduces 〉=75%.Gastroscope check mucosa chronic inflammatory disease takes a turn for the better, and histopathologic examination's body of gland atrophy, intestinal epithelial metaplasia and dysplasia recover normal or alleviate 2 level degree.
3. effective: cardinal symptom, sign are obviously improved, and integration reduces 〉=35%, and gastroscope check mucosa chronic inflammatory disease extent of disease dwindles more than 1/2, and histopathologic examination's body of gland atrophy, intestinal epithelial metaplasia and dysplasia alleviate.
4. invalid: as not reach the effective standard of art.
(3) chronic non-specific ulcerative colitis comprehensive therapeutic effect criterion:
1. produce effects (or fully alleviate): clinical symptom disappearance, colonoscope check mucosa is normal.Drug withdrawal or only use the maintenance dose medicine is observed and was not had recurrence in 6 months.
2. effective: clinical symptoms disappears substantially, and mild inflammation reaction of colonoscope check mucosa and part pseudopolyp form.
3. invalid: clinical symptoms, scope and pathologic finding do not have improvement.
4.4 statistical method
Measurement data adopts pairing or t check in groups, and enumeration data adopts X
2Check, ranked data adopt rank test.Data statistic analysis adopts the SPSS10.0 statistical package.
Clinical test results
1. baseline analysis
1.1 case source and performance: see Table 1.
Table 1 case performance
| Test unit | Add up to 1234 | Test group 1234 | Matched group 1234 |
| The 3rd Hunan Inst of Traditional Chinese Medicine Affiliated Hospital of Affiliated Hospital of second Hunan College of Traditional Chinese Medicine of Affiliated Hospital of Hunan College of Traditional Chinese Medicine | ?120???120???0????0 ?123???120???3????0 ?160???160???0????0 | ?90????90????0????0 ?92????90????2????0 ?120???120???0????0 | ?30???30???0???0 ?31???30???1???0 ?40???40???0???0 |
| Add up to | ?403???400???3????0 | ?302???300???2????0 | ?101??100??1???0 |
Annotate: 1: go into to organize case: 2: finish case: 3 cases that come off: 4 reject cases.The above case reason that comes off is and lose visits.
1.2 subject age: see Table 2.
The analysis of table 2 Dai wen moxibustion plaster clinical trial subject age (year)
| The example number | ?X±SD | ????T | ????P | |
| Treatment group matched group | ????300 ????100 | ?41.06±16.25 ?39.81±15.47 | ????0.67 | ????0.5007 |
1.3 experimenter's sex: see Table 3.
Table 3 Dai wen moxibustion plaster clinical trial experimenter sex is analyzed (example)
| The example number | The male | The women | ????X 2 | ????P | |
| The treatment group | ????300 | ????111 | ????189 | ????0.51 | ????0.4751 |
| Matched group | ????100 | ????41 | ????59 |
1.4 experimenter's course of disease: see Table 4
Table 4 Dai wen moxibustion plaster clinical trial experimenter's course of disease situation (moon)
| The example number | ????X±SD | ????T | ????P | |
| The treatment group | ????300 | ????16.61±14.51 | ????0.66 | ????0.4751 |
| Matched group | ????100 | ????15.53±13.27 |
1.5 sick kind of experimenter distributes: see Table 5:
Sick plant distribute (example) of table 5 experimenter
| The example number | Rheumatic arthritis | Chronic gastritis | Chronic colitis | ??X 2 | ????P | |
| The treatment group | ??300 | ????122 | ????91 | ????87 | ??0.17 | ????0.9162 |
| Matched group | ??100 | ????41 | ????32 | ????27 |
1.6 cold-damp resistance network or deficiency-cold syndrome card Hou Jifen: see Table 6:
Table 6 Dai wen moxibustion plaster clinical trial experimenter treats preceding Syndrome in TCM marquis integration
| The example number | ????X±SD | ????T | ????P | |
| The treatment group | ????300 | ????15.87±5.77 | ????0.99 | ????0.3205 |
| Matched group | ????100 | ????15.20±6.02 |
By last baseline analysis result as can be known, test between two groups treat before at main demography data and the equal not statistically significant of state of an illness data comparable group differences (P＞0.05), point out two groups of experimenter's distributing equilibriums, have comparability preferably.
2. efficiency evaluation result
2.1 card marquis and symptom curative effect thereof
2.1.1 curative effect overall merit: see Table 7:
Table 7 Dai wen moxibustion plaster clinical trial experimenter cold-damp resistance network or deficiency-cold syndrome marquis curative effect comprehensive evaluation result (routine %)
| The example number | Control | Produce effects | Effectively | Invalid | Obvious effective rate | Effective percentage | |
| The treatment group | 300 | ??67 | ?112 | ????93 | ????28 | ??59.67 | ????90.67 |
| Matched group | 100 | ??14 | ?34 | ????35 | ????17 | ??48.00 | ????83.00 |
Treatment group and matched group be (rank test): Z=2.35 relatively, P0.0134.
2.1.2 observed result before and after cold-damp resistance network or deficiency and coldness symptom rank scores and the card Hou Jifen treatment: see Table 8-9.
Rank scores result before and after table 8 Dai wen moxibustion plaster clinical trial experimenter cold-damp resistance network or the deficiency-cold syndrome symptom treatment (X ± SD)
| The example number | Before the treatment | After the treatment | Difference | ??T | ??P | ||
| The joint | The treatment group | ????122 | ????4.09±1.62 | ????1.84±1.19 | ????2.55±1.43 | ??1.60 | ??0.1116 |
| Pain | Matched group | ????41 | ????4.00±1.44 | ????2.15±1.33 | ????1.85±1.24 | ||
| The joint | The treatment group | ????118 | ????3.78±1.4 | ????1.51±1.26 | ????2.27±1.39 | ??0.86 | ??0.3984 |
| Tenderness | Matched group | ????40 | ????3.57±1.29 | ????1.75±1.37 | ????1.82±1.29 | ||
| Bend and stretch | The treatment group | ????104 | ????3.64±3.03 | ????1.62±1.87 | ????2.02±1.50 | ??0.76 | ??0.4517 |
| Unfavorable | Matched group | ????36 | ????3.58±2.95 | ????1.98±2.11 | ????1.60±1.19 | ||
| The joint | The treatment group | ????99 | ????3.05±1.31 | ????0.69±1.08 | ????2.29±1.23 | ??1.59 | ??0.1211 |
| Swelling | Matched group | ????32 | ????2.91±1.63 | ????1.38±1.54 | ????1.53±1.28 | ||
| The joint | The treatment group | ????93 | ????3.32±1.16 | ????0.84±1.02 | ????2.49±0.82 | ??3.47 | ??0.0015 |
| Do cold | Matched group | ????29 | ????3.14±1.23 | ????1.22±1.33 | ????1.44±0.67 | ||
| Aversion to wind | The treatment group | ????57 | ????0.97±0.66 | ????0.35±1.14 | ????0.78±0.35 | ??3.59 | ??0.0010 |
| Cold | Matched group | ????24 | ????0.99±1.30 | ????0.48±1.23 | ????0.33±0.23 | ||
| Limbs | The treatment group | ????80 | ????1.32±0.54 | ????0.40±0.79 | ????0.91±0.69 | ??1.43 | ??0.1617 |
| Heavy | Matched group | ????29 | ????1.27±0.59 | ????0.70±0.57 | ????0.54±0.61 | ||
| The gastral cavity abdomen | The treatment group | ????164 | ????2.97±0.94 | ????0.52±0.8 | ????2.45±1.20 | ??0.33 | ??0.7428 |
| Cold type of pain | Matched group | ????49 | ????2.97±1.07 | ????0.63±0.8 | ????2.34±1.46 | ||
| Stool | The treatment group | ????86 | ????1.71±1.29 | ????0.27±0.75 | ????1.44±1.12 | ??0.81 | ??0.4231 |
| Have loose bowels | Matched group | ????24 | ????1.44±1.07 | ????0.25±0.54 | ????1.20±1.16 | ||
| Stool | The treatment group | ????110 | ????1.84±1.36 | ????0.46±0.81 | ????1.39±1.24 | ??0.13 | ??0.9006 |
| Rare half congealed | Matched group | ????41 | ????1.69±1.21 | ????0.33±0.62 | ????1.35±1.11 | ||
| Indigestion and loss of appetite | The treatment group | ????130 | ????2.13±1.08 | ????0.63±1.03 | ????1.50±1.08 | ??0.04 | ??0.9709 |
| Lack of appetite | Matched group | ????43 | ????2.12±1.09 | ????0.61±0.95 | ????1.51±0.87 | ||
| Cold physique | The treatment group | ????136 | ????0.87±0.65 | ????0.31±0.49 | ????0.56±0.52 | ??0.36 | ??0.7227 |
| Cold extremities | Matched group | ????37 | ????0.85±0.60 | ????0.34±0.43 | ????0.51±0.57 | ||
| Mental fatigue | The treatment group | ????114 | ????0.89±0.37 | ????0.29±0.45 | ????0.61±0.46 | ??0.88 | ??0.3801 |
| Weak | Matched group | ????37 | ????0.72±0.55 | ????0.22±0.42 | ????0.50±0.51 | ||
| After the food | The treatment group | ????108 | ????1.01±0.58 | ????0.21±0.39 | ????0.80±0.49 | ??1.71 | ??0.0913 |
| Abdominal distention | Matched group | ????32 | ????0.87±0.44 | ????0.29±0.37 | ????0.58±0.48 |
Observed result before and after table 9 Dai wen moxibustion plaster clinical trial person cold-damp resistance network or the treatment of deficiency-cold syndrome marquis integration (X ± SD)
| The example number | Before the treatment | After the treatment | Difference | |
| The treatment group | ??300 | ????15.48±5.53 | ????4.49±6.28 | ??6.22±4.62 |
| Matched group | ??100 | ????14.67±5.49 | ????6.33±6.72 | ??5.03±3.69 |
Compare in the group: treatment group T=23.16 P=0.0000, matched group T=13.49 P=0.0000
Compare between group: T=1.26 before treating, P=0.2088 treats back T=2.47, P=0.0139, difference T=2.32 P=0.0211
2.1.3 cold-damp resistance network or deficiency-cold syndrome symptom therapeutic evaluation result: see Table 10.
Table 10 cold-damp resistance network or deficiency and coldness symptom therapeutic evaluation result (example)
| Symptom example number appears | Clinic control | Produce effects | Enabledisable | Obvious effective rate % | Effective percentage % | ????Z | ????P | |||
| The joint | The treatment group | ????122 | ????46 | ????27 | ????40 | ????9 | ??59.84 | ??92.62 | ??1.01 | ?0.3125 |
| Pain | Matched group | ????41 | ????13 | ????10 | ????10 | ????8 | ??56.10 | ??80.49 | ||
| The joint | The treatment group | ????116 | ????42 | ????16 | ????45 | ????13 | ??50.00 | ??88.79 | ??1.18 | ?0.2381 |
| Tenderness | Matched group | ????38 | ????11 | ????5 | ????14 | ????8 | ??42.11 | ??78.95 | ||
| Bend and stretch | The treatment group | ????104 | ????38 | ????14 | ????37 | ????15 | ??50.00 | ??85.58 | ??1.96 | ?0.0501 |
| Unfavorable | Matched group | ????34 | ????8 | ????5 | ????9 | ????12 | ??38.23 | ??64.71 | ||
| The joint | The treatment group | ????99 | ????60 | ????11 | ????11 | ????17 | ??71.72 | ??82.83 | ??1.62 | ?0.1065 |
| Swelling | Matched group | ????32 | ????13 | ????5 | ????7 | ????7 | ??56.25 | ??78.13 | ||
| The joint | The treatment group | ????93 | ????54 | ????13 | ????14 | ????12 | ??72.04 | ??87.10 | ??2.99 | ?0.0012 |
| Do cold | Matched group | ????29 | ????8 | ????3 | ????9 | ????9 | ??37.93 | ??68.97 | ||
| Aversion to wind | The treatment group | ????57 | ????35 | ????8 | ????9 | ????5 | ??75.44 | ??91.23 | ??3.23 | ?0.0005 |
| Cold | Matched group | ????24 | ????5 | ????5 | ????7 | ????7 | ??41.67 | ??70.83 | ||
| Limbs | The treatment group | ????80 | ????36 | ????7 | ????26 | ????11 | ??53.75 | ??86.25 | ??1.64 | ?0.0817 |
| Heavy | Matched group | ????29 | ????8 | ????3 | ????11 | ????7 | ??37.93 | ??75.86 | ||
| The gastral cavity abdomen | The treatment group | ????164 | ????87 | ????33 | ????29 | ????15 | ??73.17 | ??90.85 | ??1.02 | ?0.2693 |
| Cold type of pain | Matched group | ????49 | ????23 | ????8 | ????11 | ????7 | ??63.27 | ??85.71 | ||
| Stool | The treatment group | ????86 | ????50 | ????12 | ????12 | ????12 | ??72.09 | ??86.05 | ??0.409 | ?0.6446 |
| Have loose bowels | Matched group | ????24 | ????15 | ????2 | ????6 | ????1 | ??70.83 | ??65.83 | ||
| Stool | The treatment group | ????110 | ????59 | ????13 | ????26 | ????12 | ??65.45 | ??89.09 | ??0.03 | ?0.9780 |
| Rare half congealed | Matched group | ????41 | ????22 | ????5 | ????9 | ????5 | ??65.85 | ??87.80 | ||
| Indigestion and loss of appetite | The treatment group | ????130 | ????64 | ????16 | ????31 | ????19 | ??61.54 | ??85.38 | ??0.29 | ?0.7563 |
| Lack of appetite | Matched group | ????43 | ????21 | ????3 | ????12 | ????7 | ??55.81 | ??83.72 | ||
| Cold physique | The treatment group | ????136 | ????66 | ????11 | ????35 | ????24 | ??56.62 | ??82.35 | ??1.37 | ?0.1426 |
| Cold extremities | Matched group | ????37 | ????13 | ????2 | ????14 | ????8 | ??40.54 | ??78.38 | ||
| Mental fatigue | The treatment group | ????114 | ????51 | ????8 | ????30 | ????25 | ??51.75 | ??78.07 | ??1.22 | ?0.1964 |
| Weak | Matched group | ????37 | ????13 | ????1 | ????12 | ????11 | ??37.84 | ??70.27 | ||
| After the food | The treatment group | ????108 | ????70 | ????4 | ????13 | ????21 | ??68.52 | ??80.56 | ??1.17 | ?0.1764 |
| Abdominal distention | Matched group | ????32 | ????17 | ????1 | ????4 | ????10 | ??56.25 | ??68.75 |
2.1.4 tongue arteries and veins observed result before and after cold-damp resistance network or the deficiency-cold syndrome treatment: see Table 11.
Observed result (example) before and after table 11 Dai wen moxibustion plaster clinical trial experimenter cold-damp resistance network or deficiency-cold syndrome tongue, the arteries and veins treatment
| The example number | Occur | Do not occur | ?X 2 | P | |||
| Pale tongue or light fat | The treatment group | Before the treatment | 296 | ?241 | ?55 | ?62.38 | ＜0.0001 |
| After the treatment | 296 | ?150 | ?146 | ||||
| Matched group | Before the treatment | 98 | ?82 | ?16 | ?26.41 | ＜0.0001 | |
| After the treatment | 98 | ?48 | ?50 | ||||
| X before the treatment 2=0.25, P=0.6171; Treatment back X 2＝0.08，P＝0.7773 | |||||||
| Tongue is white or white and moist | The treatment group | Before the treatment | 296 | ?257 | ?39 | ?92.87 | ＜0.0001 |
| After the treatment | 296 | ?148 | ?148 | ||||
| Matched group | Before the treatment | 98 | ?87 | ?11 | ?31.73 | ＜0.0001 | |
| After the treatment | 98 | ?51 | ?47 | ||||
| X before the treatment 2=0.25, P=0.6171; Treatment back X 2＝0.12，P＝0.7291 | |||||||
| Stringy and tense pulse or heavy thin | The treatment group | Before the treatment | 296 | ?198 | ?98 | ?38.28 | ＜0.0001 |
| After the treatment | 296 | ?123 | ?173 | ||||
| Matched group | Before the treatment | 98 | ?64 | ?34 | ?4.70 | ?0.0301 | |
| After the treatment | 98 | ?49 | ?49 | ||||
| X before the treatment 2=0.08, P=0.7773; Treatment back X 2＝2.14，P＝0.435 | |||||||
By table 8-11 analysis result as can be known, observation interpretation of result explanation before and after cold-damp resistance network or deficiency and coldness symptom rank scores and the card Hou Jifen treatment, card marquis cardinal symptom all has clear improvement after two groups of patient's medications, and the Dai wen moxibustion plaster group improvement situations such as cylindrarthrosis cold type of pain, aversion to wind and cold of suiting the medicine to the illness are better than matched group, and relatively reaching two groups of differences of curative effect comparison with the score fall has statistical significance.
2.2 curative effect of disease and main lab index thereof are treated forward and backward testing result
2.2.1 rheumatic arthritis
(1) curative effect overall merit: see Table 12.
Table 12 Dai wen moxibustion plaster clinical trial experimenter rheumatic arthritis curative effect comprehensive evaluation result (example, %)
| The example number | Control | Produce effects | Effectively | Invalid | Obvious effective rate | Effective percentage | |
| The treatment group | ????122 | ????25 | ????45 | ????38 | ????14 | ??54.38 | ??88.52 |
| Matched group | ????41 | ????8 | ????9 | ????13 | ????11 | ??41.46 | ??73.17 |
Curative effect compares (rank test): Z=1.78, P=0.0742 between group.
(2) anti-" O " treats forward and backward testing result with erythrocyte sedimentation rate: see Table 13, table 14.
Testing result before and after table 13 Dai wen moxibustion plaster clinical trial rheumatic arthritis experimenter anti-" O " the treatment treatment
| The example number | Before the treatment | After the treatment | |||
| ??≤500U | ??＞500U | ??≤500U | ??＞500U | ||
| The treatment group | ????122 | ????57 | ????65 | ????113 | ????9 |
| Matched group | ????41 | ????18 | ????23 | ????32 | ????9 |
Compare in the group: treatment group X
2=60.82, P＜0.0001; Matched group X
2=10.05, P=0.0001.
Compare between group: before the treatment: X
2=0.10, P=0.7542 treats back X
2=6.63, P=0.01.
Testing result before and after the treatment of table 14 Dai wen moxibustion plaster clinical trial rheumatic arthritis experimenter erythrocyte sedimentation rate
| The example number | Before the treatment | After the treatment | |||
| Normally | Speed | Normally | Speed | ||
| The treatment group | ????122 | ????48 | ????74 | ????103 | ????19 |
| Matched group | ????41 | ????15 | ????26 | ????32 | ????9 |
Compare in the group: treatment group X
2=52.56, P＜0.0001; Matched group X
2=14.41, P＜0.0001.
Compare between group: before the treatment: X
2=0.10, P=0.7542 treats back X
2=0.88, P=0.3482.
2.2.2 chronic gastritis: the curative effect comprehensive evaluation result sees Table 15.
Table 15 Dai wen moxibustion plaster clinical trial experimenter chronic gastritis curative effect comprehensive evaluation result (example, %)
| The example number | Control | Produce effects | Effectively | Invalid | Obvious effective rate | Effective percentage | |
| The treatment group | ????91 | ????9 | ????15 | ????38 | ????29 | ????26.37 | ????68.13 |
| Matched group | ????32 | ????3 | ????5 | ????13 | ????11 | ????25.00 | ????65.63 |
Curative effect compares (rank test): Z=0.22, P=0.8243 between group
2.2.3 chronic enteritis
(1) curative effect overall merit: see Table 16.
Table 16 Dai wen moxibustion plaster clinical trial experimenter chronic enteritis curative effect comprehensive evaluation result (example, %)
| The example number | Produce effects | Effectively | Invalid | Obvious effective rate | Effective percentage | |
| The treatment group | ????87 | ????13 | ????38 | ????36 | ????15.12 | ????58.14 |
| Matched group | ????27 | ????3 | ????14 | ????10 | ????11.54 | ????61.58 |
Curative effect compares (rank test): Z=0.12, P=0.9043 between group.
(2) testing result before and after the stool routine examination treatment: see Table 17.
Testing result before and after the treatment of table 17 Dai wen moxibustion plaster clinical trial chronic enteritis experimenter stool routine examination
| The example number | Before the treatment | After the treatment | |||
| Normally | Bloody purulent stool | Normally | Bloody purulent stool | ||
| The treatment group | ????87 | ????55 | ????32 | ????83 | ????4 |
| Matched group | ????27 | ????16 | ????11 | ????25 | ????2 |
Compare in the group: treatment group X
2=27.46, P＜0.0001; Matched group X
2=8.21.P＝0.0042。
Compare between group: before the treatment: X
2=0.14, P=0.7113 treats back X
2=0.33, P=0.568.
By above table 12-17 analysis result as seen, two groups are detected with main lab index curative effect of disease and not to be seen notable difference.
(3) safety evaluatio result
3. adverse events: in process of the test, have 3 examples to be the treatment group, 2 examples occur outside the anaphylaxis of slight cuticle rash phenomenon for the case of the matched group local skin of applying ointment or plaster, and do not observe other obvious adverse reaction.
4. conclusion
Dai wen moxibustion plaster is made up of Fructus Capsici, Cortex Cinnamomi, Rhizoma Zingiberis Recens, Oleum Cinnamomi, the side in all medical instruments have warming middle-JIAO to promote blood circulation, cold expelling dispel the pain function.Suit with common syndrome of cold-dampness blocking collaterals and the gastric abscess (chronic gastritis) of numbness disease (rheumatic arthritis), the etiology and pathogenesis of (chronic non-specific ulcerative colitis) deficiency-cold in middle-JIAO card of having loose bowels.This product is not only easy to use, and effect is comparatively lasting, especially follows through pasting the cave in conjunction with theory of Chinese medical science is dialectical, and promoting the flow of QI-blood by warming the meridian is arranged, the merit of QI and blood regulating, thus play the promoting the circulation of blood disperse blood stasis and dredge collateral, the effect of dispersing cold for relieving pain is for its clinical efficacy is laid a good foundation.
Clinical test results shows, Dai wen moxibustion plaster is better to cold-damp resistance network or deficiency-cold syndrome marquis curative effect, main feature is for obviously improving spinal column extremities joint cold type of pain due to the rheumatic arthritis wind-cold damp pathogen resistance network, tenderness, swelling, movable unfavorable etc., coldness and pain in the epigastrium due to chronic gastroenteritis patient's deficiency-cold in middle-JIAO, the clear symptom such as rare of loose stool or diarrhea.Curative effect of disease overall merit, this product also have certain curative effect, simultaneously rheumatic arthritis patient anti-" O " are had certain restitution unusually with erythrocyte sedimentation rate and the inspection of chronic non-specific ulcerative colitis patient stool routine examination.From different curative effect of disease angle analysis, this product is better for cold dampness accumulation pattern rheumatic arthritis curative effect, is preferably kind patient's disease clinical symptoms and asthenic cold type chronic gastritis, chronic non-specific ulcerative colitis mainly acted on.Except that being subjected to reagent group 3 examples untoward reaction to occur all not finding the erythra phenomenon, safety indexes does not also go out normally to transfer to unusual in treatment or exceptional value obviously raises, reduces in this test.
The specific embodiment
Embodiment 1
A kind of rubber-emplastrum for the treatment of chronic asthenic cold type gastroenteritis, chronic rheumatic arthritis, make by following raw material that (weight: g): Fructus Capsici 4.6, Rhizoma Zingiberis Recens 3.5, Oleum Cinnamomi 0.2, Cortex Cinnamomi 1.05 and base rubber, zinc oxide, Colophonium, lanoline, proportioning ratio are 1: 1: 1: 0.22.
Preparation method:, be broken into coarse powder with the Rhizoma Zingiberis Recens drying; Pepper drying is broken into coarse powder; The Cortex Cinnamomi drying is broken into coarse powder, mixes mixture alcohol dipping three times, 24 hours for the first time, 72 hours for the second time, 48 hours for the third time, impregnation liquid filters, and merging filtrate reclaims ethanol, being condensed into relative density is the clear paste of 1.3-1.35 (70 ℃), adds the substrate of being made by rubber, zinc oxide, Colophonium, lanoline, adds the Oleum Cinnamomi mixing again, make coating, be coated with cream, cutting, the lid lining is cut into pieces, makes 360cm
2Promptly.
[character] this product is saffron lamellar rubber cream; Gas fragrance.
[discriminating] draws above-mentioned each 2ul of two solution according to the thin layer chromatography test, put respectively on same silica gel g thin-layer plate, and be developing solvent with petroleum ether (60-90 ℃)-ethyl acetate (17: 3), launch, take out, to dry, spray is with the dinitrophenylhydrazine test solution.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
(2) get the capsaicin reference substance, add ethanol and make the solution that every 1ml contains 4mg, in contrast product solution.According to thin layer chromatography (appendix VIB) test, draw need testing solution and each 10ul of above-mentioned reference substance solution under the item of [discriminating] (1), put in same silica gel G F respectively
254On the lamellae, be developing solvent, launch that taking-up is dried, and puts under the ultra-violet lamp (254nm) and inspects with petroleum ether (30-60 ℃)-dehydrated alcohol (9: 1).In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
[inspection] paste containing amount: measure according to rubber-emplastrum paste containing amount algoscopy, make solvent with ether, every 100cm
2Should be no less than 1.7g.
[usage and consumption] external according to disease, is pasted one by the acupuncture point.
Embodiment 2
A kind of rubber-emplastrum for the treatment of chronic asthenic cold type gastroenteritis, chronic rheumatic arthritis is by following raw material (weight: g) make: Fructus Capsici 3.8, Rhizoma Zingiberis 2, Oleum Cinnamomi 0.1; And base rubber, zinc oxide, Colophonium, lanoline, the proportioning ratio is 0.5: 0.5: 0.4: 0.1.
Preparation method: Rhizoma Zingiberis is broken into coarse powder; Pepper drying is broken into coarse powder; Mix mixture alcohol dipping three times, 24 hours for the first time, 72 hours for the second time, 48 hours for the third time, impregnation liquid filtered, merging filtrate reclaims ethanol, and being condensed into relative density is the clear paste of 1.3-1.35 (80 ℃), the substrate that adding is made according to the above ratio by rubber, zinc oxide, Colophonium, lanoline adds the Oleum Cinnamomi mixing again, makes coating, be coated with cream, cutting, lid lining, section, promptly.
Embodiment 3
A kind of treatment asthenic cold type chronic gastroenteritis, rheumatic arthritis rubber-emplastrum are by comprising following raw material (weight: the unguentum of g) making: Fructus Capsici 5.4, Rhizoma Zingiberis 5, Oleum Cinnamomi 0.3, Cortex Cinnamomi 1; And matrix components rubber, zinc oxide, Colophonium, lanoline, the proportioning ratio is 1.5: 1.5: 1.2: 0.2.
Preparation method: Rhizoma Zingiberis is broken into coarse powder; Pepper drying is broken into coarse powder; With the Cortex Cinnamomi drying, be broken into coarse powder, add said mixture, mixture is with 85% ethanol extraction secondary, each 2 hours, extracting liquid filtering, filtrate recycling ethanol is condensed into the clear paste of 1.2-1.3 (70 ℃) to there not being the alcohol flavor, adds the substrate that above-mentioned rubber, zinc oxide, Colophonium, lanoline are made, add the Oleum Cinnamomi mixing again, make coating, be coated with cream, cutting, the lid lining is cut into pieces, promptly.
Embodiment 4
A kind of treatment asthenic cold type chronic gastroenteritis, rheumatic arthritis rubber-emplastrum are by comprising following raw material (weight: the unguentum of g) making: Fructus Capsici 3.8, Rhizoma Zingiberis Recens 2, Oleum Cinnamomi 0.1, Cortex Cinnamomi 1.35; And base rubber, zinc oxide, Colophonium, lanoline, the proportioning ratio is 2.5: 2.5: 2.5: 0.55.
Preparation method: with embodiment 3.
Embodiment 5
A kind of treatment asthenic cold type chronic gastroenteritis, rheumatic arthritis rubber-emplastrum are by comprising following raw material (weight: the unguentum of g) making: Fructus Capsici 5.4, Rhizoma Zingiberis Recens 5, Oleum Cinnamomi 0.3; And base rubber, zinc oxide, Colophonium, lanoline, the proportioning ratio is 0.5: 0.5: 0.4: 0.1.
Preparation method: with embodiment 1, difference is the Cortex Cinnamomi drying is broken into coarse powder, adds said mixture, uses alcohol dipping.
Claims (9)
- Treat asthenic cold type chronic gastroenteritis, rheumatic arthritis rubber-emplastrum, be by the unguentum that comprises that following weight portion raw material is made: Fructus Capsici 3.8-5.4, Rhizoma Zingiberis Recens or Rhizoma Zingiberis 2-5, Oleum Cinnamomi 0.1-0.3 for 1 one kinds; And rubber-emplastrum substrate pharmaceutically commonly used.
- 2, according to treatment asthenic cold type chronic gastroenteritis, the rheumatic arthritis rubber-emplastrum of claim 1, described raw material is following weight portion raw material: Fructus Capsici 4.6, Rhizoma Zingiberis Recens or Rhizoma Zingiberis 3.5, Oleum Cinnamomi 0.2.
- 3, according to treatment asthenic cold type chronic gastroenteritis, the rheumatic arthritis rubber-emplastrum of claim 1 or 2, the proportioning ratio of described matrix components rubber, zinc oxide, Colophonium, lanoline is (0.5-2.5): (0.5-2.5): (0.4 :-2.5): (0.1-0.55).
- 4, according to treatment asthenic cold type chronic gastroenteritis, the rheumatic arthritis rubber-emplastrum of claim 3, the proportioning ratio of described matrix components rubber, zinc oxide, Colophonium, lanoline is 0.5: 0.5: 0.4: 0.1,1: 1: 1: 0.22 or 1.5: 1.5: 1.5: 0.33.
- 5, according to treatment asthenic cold type chronic gastroenteritis, the rheumatic arthritis rubber-emplastrum of claim 3, also comprise following weight portion raw material: Cortex Cinnamomi 0.75-1.35.
- 6, according to treatment asthenic cold type chronic gastroenteritis, the rheumatic arthritis rubber-emplastrum of claim 5, described Cortex Cinnamomi is following weight portion: Cortex Cinnamomi 1.05.
- 7, the treatment asthenic cold type chronic gastroenteritis of one of a kind of claim 1-6, the preparation method of rheumatic arthritis rubber-emplastrum may further comprise the steps: Rhizoma Zingiberis is broken into coarse powder or Rhizoma Zingiberis Recens drying, is broken into coarse powder; Pepper drying is broken into coarse powder; Mix, the mixture alcohol dipping, impregnation liquid filters, and filtrate recycling ethanol is condensed into clear paste, adds rubber-emplastrum substrate pharmaceutically commonly used, adds the Oleum Cinnamomi mixing again, makes coating, is coated with cream, cutting, the lid lining is cut into pieces, promptly.
- 8, according to the preparation method of the rubber-emplastrum of the treatment chronic asthenic cold type gastroenteritis of claim 7, chronic rheumatic arthritis, described mixture was with alcohol dipping three times, 24 hours for the first time, 72 hours for the second time, 48 hours for the third time, impregnation liquid filtered, merging filtrate reclaims ethanol, and being condensed into relative density is the clear paste of 1.3-1.35 (70 ℃), the substrate that adding is made by rubber, zinc oxide, Colophonium, lanoline, add the Oleum Cinnamomi mixing again, make coating, be coated with cream, cutting, the lid lining.
- 9, according to the preparation method of the rubber-emplastrum of the treatment chronic asthenic cold type gastroenteritis of claim 7 or 8, chronic rheumatic arthritis, also comprise: the Cortex Cinnamomi drying is broken into coarse powder, adds said mixture, use alcohol dipping.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100048196A CN100400095C (en) | 2005-02-02 | 2005-02-02 | Rubber plaster for treating insufficient cold type chronic gstroentertis and rheumatic arthritis and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100048196A CN100400095C (en) | 2005-02-02 | 2005-02-02 | Rubber plaster for treating insufficient cold type chronic gstroentertis and rheumatic arthritis and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1679684A true CN1679684A (en) | 2005-10-12 |
| CN100400095C CN100400095C (en) | 2008-07-09 |
Family
ID=35066690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100048196A Active CN100400095C (en) | 2005-02-02 | 2005-02-02 | Rubber plaster for treating insufficient cold type chronic gstroentertis and rheumatic arthritis and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100400095C (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101229353B (en) * | 2008-02-29 | 2011-02-09 | 四川省中医药科学院 | Medicine compounds for treating rheumatoid and atrophic arthritis |
| CN101693043B (en) * | 2009-10-30 | 2012-10-03 | 佛山德众药业有限公司 | Pharmaceutical plaster substrate, preparation method and applications thereof |
| CN104491773A (en) * | 2014-11-29 | 2015-04-08 | 徐国华 | Ginger granules and preparation method thereof |
| CN107510830A (en) * | 2017-08-22 | 2017-12-26 | 莫兆钦 | It is a kind of to treat gout, dysmenorrhoea and carsick seasick Chinese prescription and preparation method thereof |
| CN107837360A (en) * | 2017-11-17 | 2018-03-27 | 宁夏医科大学 | A kind of navel plaster, navel paster, preparation method and application method for treating chronic gastritis |
| CN107898986A (en) * | 2017-12-01 | 2018-04-13 | 李时珍医药集团有限公司 | A kind of mild moxibustion plaster and preparation method thereof |
| CN108042775A (en) * | 2017-12-13 | 2018-05-18 | 广西中医药大学 | A kind of Chinese cassia tree is bathed, the production method for the health care pack that bathes one's feet in hot water |
| CN110934737A (en) * | 2019-12-06 | 2020-03-31 | 湖南富兴飞鸽药业有限公司 | Traditional Chinese medicine plaster for moxibustion and preparation method thereof |
-
2005
- 2005-02-02 CN CNB2005100048196A patent/CN100400095C/en active Active
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101229353B (en) * | 2008-02-29 | 2011-02-09 | 四川省中医药科学院 | Medicine compounds for treating rheumatoid and atrophic arthritis |
| CN101693043B (en) * | 2009-10-30 | 2012-10-03 | 佛山德众药业有限公司 | Pharmaceutical plaster substrate, preparation method and applications thereof |
| CN104491773A (en) * | 2014-11-29 | 2015-04-08 | 徐国华 | Ginger granules and preparation method thereof |
| CN107510830A (en) * | 2017-08-22 | 2017-12-26 | 莫兆钦 | It is a kind of to treat gout, dysmenorrhoea and carsick seasick Chinese prescription and preparation method thereof |
| CN107837360A (en) * | 2017-11-17 | 2018-03-27 | 宁夏医科大学 | A kind of navel plaster, navel paster, preparation method and application method for treating chronic gastritis |
| CN107837360B (en) * | 2017-11-17 | 2020-11-24 | 宁夏医科大学 | Navel plaster and navel patch for treating chronic gastritis, and preparation method and use method thereof |
| CN107898986A (en) * | 2017-12-01 | 2018-04-13 | 李时珍医药集团有限公司 | A kind of mild moxibustion plaster and preparation method thereof |
| CN108042775A (en) * | 2017-12-13 | 2018-05-18 | 广西中医药大学 | A kind of Chinese cassia tree is bathed, the production method for the health care pack that bathes one's feet in hot water |
| CN110934737A (en) * | 2019-12-06 | 2020-03-31 | 湖南富兴飞鸽药业有限公司 | Traditional Chinese medicine plaster for moxibustion and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100400095C (en) | 2008-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1679684A (en) | Rubber plaster for treating insufficient cold type chronic gstroentertis and rheumatic arthritis and preparation thereof | |
| CN102085337B (en) | Patch for treating bronchial asthma of children | |
| CN1228074C (en) | Chinese traditional medicine for treating immune hypofunction and disfunction | |
| CN1872235A (en) | Muskiness acesodyne ointment of chasing wind, and preparation method | |
| CN1709404A (en) | Chinese patent medicine for preventing and treating apoplexia disease, and its production method and use | |
| TWI840312B (en) | A chinese medicinal composition and its application | |
| CN1092981C (en) | Medicine for curing arthralgia-syndrome resulted from wind,cold and dampness and its preparation method | |
| CN104306563A (en) | A medicine for treating primary sciatica and a preparing method thereof | |
| CN101028325A (en) | Medicinal composition containing sailonggu, and its preparation and quality control | |
| CN100335094C (en) | Notoginseng pain relieving plaster and its preparation method | |
| CN1353984A (en) | Far infrared nano plaster | |
| CN1148217C (en) | Chinese medicine for treating chronic bronchitis | |
| CN1485087A (en) | Medicine for curing cancer, the preparation process and the application thereof | |
| CN110755585B (en) | Traditional Chinese medicine foot bath agent for treating chronic insomnia and preparation method thereof | |
| CN1907452A (en) | Medicine for treating chronic colitis and its preparing process | |
| CN1840101A (en) | Chinese medicine with wind-dispelling damp-eliminating, collaterals-dredging, coldness-expelling pain-relieving functions and preparation process thereof | |
| CN1323679C (en) | Medicine for treating enteron diseases | |
| CN1544019A (en) | Chinese traditional medicine composition for treating arthralgia syndrome of cervical spondylopathy and its preparation | |
| CN1679908A (en) | Chinese medicine for treating tumor and preparation thereof | |
| CN1085091C (en) | Injecta Gankang for cold and its production | |
| CN1299711C (en) | Traditional Chinese medicine | |
| CN1184981C (en) | Antalgesic liniment | |
| CN1240658A (en) | Quickly-acting antalgesic liniment and its preparing process | |
| CN1899391A (en) | Chinese medicine preparation for treating protrasion of lumbar intervertebral disc | |
| CN1814198A (en) | Medicine for preventing bedsore resulted from Qi-stagnation and blood-stagnation, and preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HU NAN FUXING FEIGE PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: FENG SHANGSHU Effective date: 20120627 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yi Hongbo Inventor before: Feng Shangshu |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: FENG SHANGSHU TO: YI HONGBO Free format text: CORRECT: ADDRESS; FROM: 411101 XIANGTAN, HUNAN PROVINCE TO: 411102 XIANGTAN, HUNAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20120627 Address after: 411102 Hunan Province, Xiangtan city Yuetang District Shuangma Industrial Park No. 1 Patentee after: Hunan Fuxing Feige Pharmaceutical Co., Ltd. Address before: 411101, No. 2, unit 1, building 15, 22 West Shaoshan Road, Yuhu District, Hunan, Xiangtan Patentee before: Feng Shangshu |